Key result
Neoadjuvant chemotherapy resulted in a good clinical response and nearly 3 years of disease-free survival in a 12-year-old girl with extraosseous osteosarcoma and pulmonary metastases.
Why the study?
Does combined modality therapy improve outcomes in children with extraosseous osteosarcoma?
Case Report (n=1)
Does combined modality therapy improve outcomes in children with extraosseous osteosarcoma?
Children with extraosseous osteosarcoma may have a more favorable response to combined modality therapy than adults.
May support neoadjuvant chemotherapy in select pediatric extraosseous osteosarcoma; leaves open generalizability from this single case.
Osteosarcoma arising in soft tissues is exceedingly rare in children. The tumor most often affects older adults, involves the lower extremity, responds poorly to chemotherapy, and carries a grave prognosis. The authors describe a 12-year-old girl with an extraosseous osteosarcoma of the left sternocleidomastoid muscle with pulmonary metastases. The patient responded well to neoadjuvant chemotherapy and remains disease-free nearly 3 years after her initial diagnosis. The authors review available information about this disease in children and adults. Children with extraosseous osteosarcoma may have a more favorable response to treatment than adults; thus, a curative approach using combined modality therapy appears warranted.
No takes yet. Share an insight, caveat, or question.
Wodowski et al. (2003) conducted a case report in Extraosseous osteosarcoma (n=1). Neoadjuvant chemotherapy was evaluated on Disease-free survival. Neoadjuvant chemotherapy resulted in a good clinical response and nearly 3 years of disease-free survival in a 12-year-old girl with extraosseous osteosarcoma and pulmonary metastases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: